160 related articles for article (PubMed ID: 36900421)
1. DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer.
Sigin VO; Kalinkin AI; Nikolaeva AF; Ignatova EO; Kuznetsova EB; Chesnokova GG; Litviakov NV; Tsyganov MM; Ibragimova MK; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900421
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer.
Sigin VO; Kalinkin AI; Kuznetsova EB; Simonova OA; Chesnokova GG; Litviakov NV; Slonimskaya EM; Tsyganov MM; Ibragimova MK; Volodin IV; Vinogradov II; Vinogradov MI; Vinogradov IY; Kutsev SI; Strelnikov VV; Zaletaev DV; Tanas AS
Sci Rep; 2020 Jun; 10(1):9239. PubMed ID: 32514046
[TBL] [Abstract][Full Text] [Related]
3. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
4. Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.
Díaz C; González-Olmedo C; Díaz-Beltrán L; Camacho J; Mena García P; Martín-Blázquez A; Fernández-Navarro M; Ortega-Granados AL; Gálvez-Montosa F; Marchal JA; Vicente F; Pérez Del Palacio J; Sánchez-Rovira P
Mol Oncol; 2022 Jul; 16(14):2658-2671. PubMed ID: 35338693
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and
Sadzeviciene I; Snipaitiene K; Scesnaite-Jerdiakova A; Daniunaite K; Sabaliauskaite R; Laurinaviciene A; Drobniene M; Ostapenko V; Jarmalaite S
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499753
[TBL] [Abstract][Full Text] [Related]
8. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
Richard R; Thomassin I; Chapellier M; Scemama A; de Cremoux P; Varna M; Giacchetti S; Espié M; de Kerviler E; de Bazelaire C
Eur Radiol; 2013 Sep; 23(9):2420-31. PubMed ID: 23652844
[TBL] [Abstract][Full Text] [Related]
10. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers.
Ortmann O; Blohmer JU; Sibert NT; Brucker S; Janni W; Wöckel A; Scharl A; Dieng S; Ferencz J; Inwald EC; Wesselmann S; Kowalski C;
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1195-1209. PubMed ID: 35380257
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa.
Ruff P; Cubasch H; Joffe M; Rosenbaum E; Murugan N; Tsai MC; Ayeni O; Crew KD; Jacobson JS; Neugut AI
Cancer Manag Res; 2018; 10():279-286. PubMed ID: 29467582
[TBL] [Abstract][Full Text] [Related]
12. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
[TBL] [Abstract][Full Text] [Related]
13. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
14. Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer.
Timme S; Sillem M; Bronsert P; Bogatyreva L; Hauschke D; Zur Hausen A; Werner M; Stickeler E
Breast Care (Basel); 2017 Sep; 12(4):244-250. PubMed ID: 29070988
[TBL] [Abstract][Full Text] [Related]
15. Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
De Caluwé A; Buisseret L; Poortmans P; Van Gestel D; Salgado R; Sotiriou C; Larsimont D; Paesmans M; Craciun L; Stylianos D; Vandekerckhove C; Reyal F; Isabelle V; Eiger D; Piccart M; Romano E; Ignatiadis M
BMC Cancer; 2021 Aug; 21(1):899. PubMed ID: 34362344
[TBL] [Abstract][Full Text] [Related]
16. Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis.
Kolberg HC; Kühn T; Krajewska M; Bauerfeind I; Fehm TN; Fleige B; Helms G; Lebeau A; Stäbler A; Schmatloch S; Hausschild M; Schwentner L; Schrenk P; Loibl S; Untch M; Kolberg-Liedtke C
Geburtshilfe Frauenheilkd; 2020 Dec; 80(12):1229-1236. PubMed ID: 33293731
[No Abstract] [Full Text] [Related]
17. Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial.
Edlund K; Madjar K; Lebrecht A; Aktas B; Pilch H; Hoffmann G; Hofmann M; Kolberg HC; Boehm D; Battista M; Seehase M; Stewen K; Gebhard S; Cadenas C; Marchan R; Brenner W; Hasenburg A; Koelbl H; Solbach C; Gehrmann M; Tanner B; Weber KE; Loibl S; Sachinidis A; Rahnenführer J; Schmidt M; Hengstler JG
Clin Cancer Res; 2021 Apr; 27(8):2148-2158. PubMed ID: 33542080
[TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Huober J; von Minckwitz G; Denkert C; Tesch H; Weiss E; Zahm DM; Belau A; Khandan F; Hauschild M; Thomssen C; Högel B; Darb-Esfahani S; Mehta K; Loibl S
Breast Cancer Res Treat; 2010 Nov; 124(1):133-40. PubMed ID: 20697801
[TBL] [Abstract][Full Text] [Related]
19. Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response.
Lee HC; Ko H; Seol H; Noh DY; Han W; Kim TY; Im SA; Park IA
J Breast Cancer; 2013 Dec; 16(4):395-403. PubMed ID: 24454461
[TBL] [Abstract][Full Text] [Related]
20. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.
McGuire A; Casey MC; Waldron RM; Heneghan H; Kalinina O; Holian E; McDermott A; Lowery AJ; Newell J; Dwyer RM; Miller N; Keane M; Brown JAL; Kerin MJ
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
